| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Institut National de la Santé et de la Recherche Médicale Unité 477, Université René Descartes, Paris, France;
Service de Chirurgie Digestive, Hôpital Henri Mondor, Université Paris XII, Creteil, France;
Laboratoire d’Immunologie, Hôpital Cochin, Université René Descartes, Paris, France;
Service d’anatomie et cytologie pathologiques, Centre Hospitalo-Universitaire de Bicêtre, Le Kremlin-Bicêtre, France; and
¶ Institut National de la Santé et de la Recherche Médicale Unité 257, Université René Descartes, Paris, France
Constitutive Fas ligand (FasL) expression by specialized cells in the body participates in the immune privilege status of tissues containing these cells. This property has been used to prevent rejection of allogeneic grafts. Nevertheless, the mechanism responsible for such protection has not been fully elucidated. Unfortunately, grafting of FasL transgenic (TG) tissues has been unsuccessful. We have generated TG mice expressing FasL (soluble + membrane bound) on thyroid follicular cells (TFC), and used them to show that ectopic FasL expression prevents thyroid allograft rejection. FasL expression on TFC led to markedly decreased anti-allogeneic, cytotoxic, and helper T lymphocyte activities. The alloantibody response in TG thyroid recipients was either completely inhibited or switched toward a T2-Ab response. Surprisingly, the beneficial effect of FasL on TG thyroid grafts was abolished by host CD4+ T cell depletion. Host CD8+ T cell depletion improved nontransgenic (NTG), but not TG graft survival. Altogether, our results suggest that FasL-induced tolerance is concomitant with a move away from a T1 type response, and a CD4 T cell-mediated regulation of the allocytotoxic T cell response. These results were dependent upon the level of FasL expression on TFC, in that low expression of FasL led to a less marked effect compared with the effect observed with high expression of FasL. These results provide some insight into the role of FasL in regulating destructive alloimmune responses in the case of whole organ grafting, and they have important implications for the development of FasL-based immunotherapy in organ transplantation.
This article has been cited by other articles:
|
|
 |
|
  S. Buonocore, N. O. Haddou, F. Moore, S. Florquin, F. Paulart, C. Heirman, K. Thielemans, M. Goldman, and V. Flamand Neutrophil-dependent tumor rejection and priming of tumoricidal CD8+ T cell response induced by dendritic cells overexpressing CD95L J. Leukoc. Biol., September 1, 2008; 84(3): 713 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Yolcu, X. Gu, C. Lacelle, H. Zhao, L. Bandura-Morgan, N. Askenasy, and H. Shirwan Induction of Tolerance to Cardiac Allografts Using Donor Splenocytes Engineered to Display on Their Surface an Exogenous Fas Ligand Protein J. Immunol., July 15, 2008; 181(2): 931 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Ryan, F. Shanahan, J. O'Connell, and A. M. Houston Addressing the "Fas Counterattack" Controversy: Blocking Fas Ligand Expression Suppresses Tumor Immune Evasion of Colon Cancer In vivo Cancer Res., November 1, 2005; 65(21): 9817 - 9823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Askenasy, E. S. Yolcu, I. Yaniv, and H. Shirwan Induction of tolerance using Fas ligand: a double-edged immunomodulator Blood, February 15, 2005; 105(4): 1396 - 1404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Bohana-Kashtan and C. I. Civin Fas Ligand as a Tool for Immunosuppression and Generation of Immune Tolerance Stem Cells, November 1, 2004; 22(6): 908 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yang, K. Sato, T. Aprahamian, N. J. Brown, J. Hutcheson, A. Bialik, H. Perlman, and K. Walsh Endothelial Overexpression of Fas Ligand Decreases Atherosclerosis in Apolipoprotein E-Deficient Mice Arterioscler. Thromb. Vasc. Biol., August 1, 2004; 24(8): 1466 - 1473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yang, S. P. Jones, T. Suhara, J. J. M. Greer, P. D. Ware, N. P. Nguyen, H. Perlman, D. P. Nelson, D. J. Lefer, and K. Walsh Endothelial Cell Overexpression of Fas Ligand Attenuates Ischemia-Reperfusion Injury in the Heart J. Biol. Chem., April 18, 2003; 278(17): 15185 - 15191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Whartenby, E. E. Straley, H. Kim, F. Racke, V. Tanavde, K. S. Gorski, L. Cheng, D. M. Pardoll, and C. I. Civin Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation Blood, October 16, 2002; 100(9): 3147 - 3154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Young, L. Yang, M. J. Phillips, and L. Zhang Donor-lymphocyte infusion induces transplantation tolerance by activating systemic and graft-infiltrating double-negative regulatory T cells Blood, October 16, 2002; 100(9): 3408 - 3414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Zhu, L. Luo, Y. Chen, D. W. Paty, and M. S. Cynader Intrathecal Fas Ligand Infusion Strengthens Immunoprivilege of Central Nervous System and Suppresses Experimental Autoimmune Encephalomyelitis J. Immunol., August 1, 2002; 169(3): 1561 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wei, K. Chen, G. C. Sharp, H. Yagita, and H. Braley-Mullen Expression and Regulation of Fas and Fas Ligand on Thyrocytes and Infiltrating Cells During Induction and Resolution of Granulomatous Experimental Autoimmune Thyroiditis J. Immunol., December 1, 2001; 167(11): 6678 - 6686. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
